Valuation: Beta Bionics, Inc.

Market Cap 721M 631M 582M 538M 1.02B 68.82B 1.04B 6.97B 2.73B 33.8B 2.71B 2.65B 117B P/E 2026 *
-7.29x
P/E 2027 * -7.35x
Enterprise Value 547M 478M 441M 408M 775M 52.19B 788M 5.28B 2.07B 25.63B 2.05B 2.01B 88.78B EV / Sales 2026 *
4.09x
EV / Sales 2027 * 3.45x
Free-Float
98.91%
Yield 2026 *
-
Yield 2027 * -
1 day+0.46%
1 week-3.31%
Current month+3.41%
1 month+12.61%
3 months+68.28%
6 months-19.54%
Current year-46.82%
1 week 15.68
Extreme 15.68
17.57
1 month 13.02
Extreme 13.02
17.57
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap.
06-29Fiscal year

Chief Financial Officer

14,688 0.0330%
06-29Fiscal year

Chief Financial Officer

14,688 0.0330%
06-24Sell

Executive/Senior Manager

-1,258 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%-3.31%+22.03% - 721M
+2.13%-0.28%+24.32%+0.99% 190B
-0.60%-3.21%-21.92%+21.18% 147B
+1.94%-1.65%-3.13%-16.97% 135B
+0.22%-0.76%-56.49%-15.00% 66.6B
-2.32%-3.30%+18.23%-0.41% 53.92B
+0.38%-1.66%-27.47%-30.84% 43.57B
+2.65%+1.47%+9.32%+12.04% 36.45B
+2.30%-0.60%+7.97%+42.46% 36.15B
+1.09%-1.04%-18.96%-4.23% 29.69B
Average +0.87%+0.78%-4.61%+1.02% 73.87B
Weighted average by Cap. +0.98%+1.62%-3.97%+0.67%

Financials

2026 *2027 *
Net sales 134M 117M 108M 99.78M 189M 12.76B 193M 1.29B 506M 6.27B 502M 491M 21.7B 181M 158M 146M 135M 256M 17.26B 260M 1.75B 685M 8.47B 679M 664M 29.35B
Net income -99.27M -86.84M -80.08M -74.1M -141M -9.48B -143M -959M -376M -4.65B -373M -365M -16.12B -98.46M -86.13M -79.43M -73.49M -139M -9.4B -142M -951M -373M -4.61B -370M -362M -15.99B
Net Debt -174M -152M -141M -130M -247M -16.63B -251M -1.68B -660M -8.17B -654M -640M -28.29B -97.89M -85.63M -78.97M -73.06M -139M -9.34B -141M -946M -371M -4.59B -367M -360M -15.89B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
09/07/26 $16.17 -0.09% 180,549
08/07/26 $16.18 -4.82% 999,485
07/07/26 $17.00 +1.67% 787,233
06/07/26 $16.72 -0.24% 694,655
02/07/26 $16.76 +0.36% 606,898
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
16.18USD
Average target price
19.18USD
Spread / Average Target
+18.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock